PACE

PROVIDER BULLETIN

September 30, 2014

ProDUR Edit Additions

Effective October 22, 2014, the following pharmaceuticals will be included in the PACE Prospective Drug Utilization Review (ProDUR):

THERAPEUTIC DUPLICATION

Adempas®, Opsumit®, Tracleer®, Letairis®, Adcirca®, Ventavis®, Flolan®, Veletri® and Revatio®

PLAN PROTOCOL

Naftin® and Zorvolex®

Claims for Naftin® and Zorvolex® will be stopped at the point of sale with a "Call Help Desk" message. Providers should contact Provider Services at 1-800-835-4080. A Medical Exception *may* be granted upon review.